Haythem Ali

6.5k citations

51 papers · 1.8k indexed · 1 hit paper · h-index 15

Oncology top 5%
Endocrinology, Diabetes and Metabolism top 2%
Pulmonary and Respiratory Medicine top 5%
Molecular Biology
Cancer Research top 10%

Co-authors: Steven I. Sherman Patrick Schöffski Michael C. Kreißl Rossella Elisei Ezra E.W. Cohen Barry D. Nelkin Stefan Müller Manisha H. Shah
Topics: Breast Cancer Treatment Studies (10 papers)Global Cancer Incidence and Screening (7 papers)Head and Neck Cancer Studies (7 papers)
Cited by: Endocrinology, Diabetes and Metabolism Oncology Cancer Research
Journals: Journal of Clinical Oncology PLoS ONE Cancer
Partner nations: United States United Kingdom Germany

In The Last Decade

Haythem Ali

51 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cabozantinib in Progressive Medullary Thyroid Cancer

2013 850 citations Rossella Elisei, Martin Schlumberger et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Haythem Ali

Since Specialization

Citations

This map shows the geographic impact of Haythem Ali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haythem Ali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haythem Ali more than expected).

Fields of papers citing papers by Haythem Ali

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haythem Ali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haythem Ali. The network helps show where Haythem Ali may publish in the future.

Co-authorship network of co-authors of Haythem Ali

This figure shows the co-authorship network connecting the top 25 collaborators of Haythem Ali. A scholar is included among the top collaborators of Haythem Ali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haythem Ali. Haythem Ali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Percutaneous Cholecystostomy in Severe Acute Cholecystitis: An Observational Study From a Single Institute 2023 ·Cureus ·(unknown),(unknown),Balaji Jayasankar,(unknown),Haythem Ali,(unknown)	6
2	Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model 2023 ·Cancers ·(unknown),Branislava Janic,(unknown),Harshit Singh,Haythem Ali,Ramandeep Rattan,Mohsin Kazi,Meser M. Ali	11
3	A phase I clinical trial of oncolytic adenovirus mediated suicide and interleukin-12 gene therapy in patients with recurrent localized prostate adenocarcinoma 2023 ·PLoS ONE ·Shyam Nyati,Hans Stricker,Kenneth Barton,(unknown),Mohamed A. Elshaikh,Haythem Ali,Stephen L. Brown,Clara Hwang,James O. Peabody,Svend O. Freytag,Benjamin Movsas,Farzan Siddiqui	13
4	Short-term changes in ultrasound tomography measures of breast density and treatment-associated endocrine symptoms after tamoxifen therapy 2023 ·npj Breast Cancer ·Cody Ramin,Ruth M. Pfeiffer,(unknown),Maeve Mullooly,Roni T. Falk,Kristine Jones,Neil E. Caporaso,Lisa Bey‐Knight,Mark Sak,Michael S. Simon,David H. Gorski,Haythem Ali,Peter J. Littrup,Neb Duric,Mark E. Sherman,Gretchen L. Gierach	2
5	Cetuximab and anemia prevention in head and neck cancer patients undergoing radiotherapy 2022 ·BMC Cancer ·(unknown),A.I. Ghanem,(unknown),Amy Tang,(unknown),(unknown),Haythem Ali,Steven Chang,Samantha Tam,Vivian Wu,Farzan Siddiqui,(unknown)	4
6	Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma 2021 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown),Ankit Modh,Haythem Ali,(unknown),Steven Chang,Tamer Ghanem,(unknown),Vivian Wu,Samantha Tam,(unknown),Xiaoxia Han,(unknown),Benjamin Movsas,Farzan Siddiqui	11
7	The importance of cancer patients' functional recollections to explore the acceptability of an isometric‐resistance exercise intervention: A qualitative study 2020 ·Health Science Reports ·(unknown),(unknown),David Stephensen,Ian Swaine,Haythem Ali,(unknown)	1
8	A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment 2018 ·Clinical Cancer Research ·Meredith C. Henderson,Michael Silver,(unknown),(unknown),(unknown),David E. Reese,Ana P. Lourenço,Joshua LaBaer,Karen S. Anderson,(unknown),(unknown),Nitin Rohatgi,Haythem Ali,(unknown),Donald W. Northfelt,Karthik Ghosh,Stephen R. Grobmyer,(unknown),Judith K. Wolf	17
9	nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2 2018 ·Frontiers in Oncology ·Ajeet Gajra,Nagla Abdel Karim,Deborah Mulford,(unknown),Marc Matrana,Haythem Ali,Edgardo S. Santos,Tymara Berry,Teng Jin Ong,Alexandra Sanford,Katayoun I. Amiri,David R. Spigel	10
10	Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer 2018 ·Breast Cancer Research and Treatment ·Aditya Bardia,Ayca Gucalp,(unknown),Nashat Gabrail,Michael Danso,Haythem Ali,Kimberly Blackwell,Lisa A. Carey,Joel R. Eisner,Edwina Baskin-Bey,Tiffany A. Traina	35
11	nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial 2018 ·Annals of Oncology ·Denise A. Yardley,Rob Coleman,Pierfranco Conté,Javier Cortés,Adam Brufsky,Mikhail Shtivelband,Robyn R. Young,Carmelo Bengala,Haythem Ali,(unknown),Andreas Schneeweiß,Luis de la Cruz‐Merino,Sharon Wilks,Joyce O’Shaughnessy,Stefan Glück,(unknown),Judith Miller,Débora Barton,Nadia Harbeck	91
12	Utilization of the 21-Gene Recurrence Score in a Diverse Breast Cancer Patient Population: Development of a Clinicopathologic Model to Predict High-Risk Scores and Response to Neoadjuvant Chemotherapy 2018 ·Annals of Surgical Oncology ·Ko Un Park,Yalei Chen,Dhananjay Chitale,(unknown),Haythem Ali,David Nathanson,Jessica Bensenhaver,Erica Proctor,Lindsay F. Petersen,Randa Loutfi,(unknown),(unknown),Thomas J. Doyle,(unknown),(unknown),Melissa B. Davis,Lisa A. Newman	8
13	Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer 2018 ·Hormones and Cancer ·Jessica L. Christenson,Jane B. Trepel,Haythem Ali,Sunmin Lee,Joel R. Eisner,Edwina Baskin-Bey,Anthony Elias,Jennifer K. Richer	21
14	Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma 2017 ·Annals of Oncology ·Martin Schlumberger,Rossella Elisei,Stefan Müller,Patrick Schöffski,Marcia S. Brose,Manisha H. Shah,Lisa Licitra,Jolanta Krajewska,Michael C. Kreißl,Bruno Niederle,Ezra E.W. Cohen,Lori J. Wirth,Haythem Ali,D O Clary,Yifah Yaron,Milan Mangeshkar,Douglas W. Ball,Barry D. Nelkin,Steven I. Sherman	170
15	Using Speed of Sound Imaging to Characterize Breast Density 2016 ·Ultrasound in Medicine & Biology ·Mark Sak,Neb Duric,Peter J. Littrup,Lisa Bey‐Knight,Haythem Ali,(unknown),Mark E. Sherman,Gretchen L. Gierach	53
16	Interim safety results from the phase 2 ABOUND.PS2 study evaluating nab-paclitaxel (nab-P) + carboplatin (C) followed by nab-P monotherapy in patients (pts) with NSCLC and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 2016 ·Annals of Oncology ·Ajeet Gajra,Haythem Ali,Katayoun I. Amiri,Nagla Abdel Karim,Marc Matrana,Deborah Mulford,Teng Jin Ong,(unknown),Edgardo S. Santos,Mark A. Socinski,David R. Spigel,Rogério Lilenbaum	1
17	Randomized trial of a question prompt list to increase patient active participation during interactions with black patients and their oncologists 2016 ·Patient Education and Counseling ·Susan Eggly,Lauren M. Hamel,Tanina Foster,Terrance L. Albrecht,Robert Chapman,Felicity W. K. Harper,Hayley S. Thompson,Jennifer J. Griggs,Richard Gonzalez,(unknown),Rifky Tkatch,Michael S. Simon,Anthony F. Shields,Shirish M. Gadgeel,Randa Loutfi,Haythem Ali,Ira Wollner,Louis A. Penner	60
18	Black necrotic oesophagus following the use of biodegradable stent for benign oesophageal stricture: Figure 1: 2015 ·Journal of Surgical Case Reports ·(unknown),Sanjoy Basu,Haythem Ali,Ahmed Hamouda	13
19	Cabozantinib in Progressive Medullary Thyroid Cancerbreakdown → 2013 ·Journal of Clinical Oncology ·Rossella Elisei,Martin Schlumberger,Stefan Müller,Patrick Schöffski,Marcia S. Brose,Manisha H. Shah,Lisa Licitra,Barbara Jarząb,В. С. Медведев,Michael C. Kreißl,Bruno Niederle,Ezra E.W. Cohen,Lori J. Wirth,Haythem Ali,Colin Hessel,Yifah Yaron,Douglas W. Ball,Barry D. Nelkin,Steven I. Sherman	850
20	Unusual hernia in a colostomy closure site 2009 ·Annals of The Royal College of Surgeons of England ·(unknown),(unknown),(unknown),(unknown),Haythem Ali,(unknown)	1

About Haythem Ali

Haythem Ali is a scholar working on Otorhinolaryngology, Oncology and Cancer Research, having authored 51 papers that have together received 1.8k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (10 papers), Global Cancer Incidence and Screening (7 papers) and Head and Neck Cancer Studies (7 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (632 citations), Oncology (767 citations) and Cancer Research (304 citations). Haythem Ali has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Steven I. Sherman, Patrick Schöffski, Michael C. Kreißl, Rossella Elisei, Ezra E.W. Cohen, Barry D. Nelkin, Stefan Müller, Manisha H. Shah, Douglas W. Ball and Marcia S. Brose. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact